Log In
Print
BCIQ
Print
Print this Print this
 

Extina, ketoconazole

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionFoam formulation of 2% ketoconazole
Molecular Target Cytochrome P450 C-14 alpha demethylase (CYP51)
Mechanism of ActionCytochrome P450 C-14 alpha demethylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat seborrheic dermatitis; Treat seborrheic dermatitis fungal infections
Regulatory Designation

Partner

Renaissance Acquisition Holdings LLC


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today